Management of urinary tract infections in the era of antimicrobial resistance


  • Ria Pothoven Florence and Andros Gynos Klinieken, The Hague, The Netherlands



Antibiotic, Antibiotic sparing, Antimicrobial resistance, Prophylaxis, Recurrence, Urinary tract infections


Urinary tract infections (UTIs) are among the most common infections globally, imposing a substantial personal and economic burden on individuals and health resources. Despite international health concerns and sustained public awareness campaigns about the emergence of resistant microorganisms through the inappropriate therapeutic use of antimicrobial agents, the problem of antimicrobial resistance (AMR) is worsening, and AMR in UTIs represents a critical global healthcare issue. This narrative review summarizes evidence-based scientific material, recommendations from the current medical literature, and the latest clinical guidelines on antibiotic and antibiotic-sparing strategies for managing urological infections, including practical approaches to improve the management of patients with acute and recurrent UTIs (rUTIs) in routine clinical practice. Novel emerging therapies and prophylaxis options are described as potential alternatives to overcome the abuse and overuse of antibiotics and the practical application of the guideline recommendations and issues relating to best practice in managing UTIs.


Download data is not yet available.


Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: a worldwide report. Front Public Health. 2022;10:888205. PMID:35968451 DOI:

Zeng Z, Zhan J, Zhang K, Chen H, Cheng S. Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World J Urol. 2022;40(3):755-763. PMID:35066637 DOI:

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-1249. PMID: 33069327 DOI:

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. PMID: 33069326 DOI:

Department of Health and Social Care (DHSC). UK antimicrobial resistance strategy and action plan. 2000. (Accessed March 2023).

Murray CJL, Ikuta KS, Sharara F, et al; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. PMID:35065702 DOI:

O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. (Accessed March 2023).

Bonkat G, Bartoletti R, Bruyere F, et al. EAU Guidelines on Urological Infections. Edn. presented at the EAU Annual Congress, Milan, Italy, 2023. ISBN 978-94-92671-19-6. (Accessed March 2023).

GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-2248. PMID: 36423648 DOI:

Johansen TE, Botto H, Cek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011;38(suppl):64-70. PMID:22018988 DOI:

Köves B, Cai T, Veeratterapillay R, et al. Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol. 2017;72(6):865-868. PMID:28754533 DOI:

Deltourbe L, Lacerda Mariano L, Hreha TN, Hunstad DA, Ingersoll MA. The impact of biological sex on diseases of the urinary tract. Mucosal Immunol. 2022;15(5):857-866. PMID:35869147 DOI:

Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653-660. PMID:21139641 DOI:

Ingersoll MA. Sex differences shape the response to infectious diseases. PLoS Pathog. 2017;13(12):e1006688. PMID:29284060 DOI:

Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989;110(2):138-150. PMID:2462391 DOI:

Zeng G, Zhu W, Lam W, Bayramgil A. Treatment of urinary tract infections in the old and fragile. World J Urol. 2020;38(11):2709-2720. PMID:32221713 DOI:

Dias SP, Brouwer MC, van de Beek D. Sex and gender differences in bacterial infections. Infect Immun. 2022;90(10):e0028322. PMID:36121220 DOI:

Ligon MM, Joshi CS, Fashemi BE, Salazar AM, Mysorekar IU. Effects of aging on urinary tract epithelial homeostasis and immunity. Dev Biol. 2023;493:29-39. PMID:36368522 DOI:

Zychlinsky Scharff A, Rousseau M, Lacerda Mariano L, et al. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection. JCI Insight. 2019;5(13):e122998. PMID:31145099 PMID:31145099 DOI:

Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34-42. PMID:35536143 PMID:35536143 DOI:

Nambiar AK, Arlandis S, Bø K, et al. European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49-59. PMID:35216856 DOI:

Wagenlehner FME, Bjerklund Johansen TE, Cai T, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17(10):586-600. PMID:32843751 DOI:

Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164-1175. PMID: 18511178 DOI:

Tandoğdu Z, Bartoletti R, Cai T, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol. 2016;34(8):1193-1200. PMID:26658886 DOI:

Kaußner Y, Röver C, Heinz J, et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect. 2022;28(12):1558-1566. PMID:35788049 DOI:

Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376:e068229. PMID:35264408 DOI:

Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544. PMID:26698878 DOI:

European Medicines Agency (EMA). Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA/795349/2018. 2018. Accessed March 2023.

Mohapatra S, Panigrahy R, Tak V, et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. Access Microbiol. 2022;4(2):000321. PMID:35355869 DOI:

Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):107-117. PMID:28737469 DOI:

Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509-1515. PMID:30285042 DOI:

Kyriakides R, Jones P, Somani BK. Role of D-mannose in the prevention of recurrent urinary tract infections: evidence from a systematic review of the literature. Eur Urol Focus. 2021;7(5):1166-1169. PMID:32972899 DOI:

Prattley S, Geraghty R, Moore M, Somani BK. Role of vaccines for recurrent urinary tract infections: A systematic review. Eur Urol Focus. 2020;6(3):593-604. PMID:31806578 DOI:

Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018;15(12):750-776. PMID:30361493 DOI:

Anger JT, Bixler BR, Holmes RS, Lee UJ, Santiago-Lastra Y, Selph SS. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. J Urol. 2022;208(3):536-541. PMID:35942788 DOI:

Moussa M, Abou Chakra M, Dellis A, Moussa Y, Papatsoris A. Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert Opin Pharmacother. 2020;21(16):2011-2026. PMID:32717156 DOI:

Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG. A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol Int. 2015;95(2):167-176. PMID:25721866 DOI:

Vallée M, Bruyère F. Non-antimicrobial prophylactic measures in recurrent urinary tract infections. In: Bjerklund Johansen TEWF, Matsumoto T, Cho YH, Krieger JN, Shoskes D, Naber KG, eds. Urogenital infections and inflammations. German Medical Science GMS; 2022, Version 2022-02-03. Downloaded March 22, 2023, from

Wawrysiuk S, Naber K, Rechberger T, Miotla P. Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review. Arch Gynecol Obstet. 2019;300(4):821-828. PMID:31350663 DOI:

Loubet P, Ranfaing J, Dinh A, et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front Microbiol. 2020;11:1509. PMID:32719668 PMID:32719668 DOI:

Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;4(4):CD001321. PMID:37068952 DOI:

Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022;8(8):CD013608. PMID:36041061 DOI:

Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD003265. PMID:23076896 DOI:

Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2022;33(3):571-580. PMID:34115162 DOI:

Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59(4):645-651. PMID:21272992 DOI:

Ciani O, Arendsen E, Romancik M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open. 2016;6(3):e009669. PMID:27033958 DOI:

Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933-942. PMID:29181550 DOI:

Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. PMID:31105774 PMID:31105774 DOI:

Krinitski D, Kasina R, Klöppel S, Lenouvel E. Associations of delirium with urinary tract infections and asymptomatic bacteriuria in adults aged 65 and older: A systematic review and meta-analysis. J Am Geriatr Soc. 2021;69(11):3312-3323. PMID:34448496 DOI:

Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009;57(6):963-970. PMID:19490243 DOI:

Kwok M, McGeorge S, Mayer-Coverdale J, et al. Guideline of guidelines: management of recurrent urinary tract infections in women. BJU Int. 2022;130(suppl 3):11-22. PMID:35579121 DOI:

Pigrau C, Escolà-Vergé L. Recurrent urinary tract infections: from pathogenesis to prevention. Med Clin (Barc). 2020;155(4):171-177. PMID:32561190 DOI:

Lovasz S. Minimally invasive device for intravesical instillation by urological syringe adapter (MID-ii U.S.A.) for catheter-free instillation therapy of the bladder in interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26(suppl 1):57-60. PMID:31144753 DOI:

Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. PMID:26903338 DOI:



How to Cite

Pothoven, R. (2023). Management of urinary tract infections in the era of antimicrobial resistance. Drug Target Insights, 17(1), 126–137.
Received 2023-09-11
Accepted 2023-11-21
Published 2023-12-20